Buy-rated reports

511 tickers rated Buy
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Kontoor Brands, Inc.
KTB·Consumer Discretionary
A ★★★★Buy
Current$77.06
Target$92.40
Return+19.9%
Nov 8, 2026

Kontoor Brands offers attractive normalized earnings growth and shareholder returns through Wrangler, Helly Hansen, and portfolio simplification, although integration execution, apparel cyclicality, and leverage remain important risks.

Score
81
Paylocity Holding Corporation
PCTY·Technology
A ★★★★Buy
Current$173.15
Target$193.60
Return+11.8%
Nov 8, 2026

Paylocity combines sticky payroll software, strong cash generation, and expanding enterprise workflows with a relatively attractive valuation, although slower growth and intense HCM competition could constrain future returns.

Score
81
NNN REIT, Inc.
NNN·Real Estate
A ★★★★Buy
Current$41.12
Target$45.88
Return+11.6%
Nov 7, 2026

NNN REIT offers durable triple-net rental cash flows, a 37-year dividend-growth record, and an attractive income yield, although interest-rate sensitivity, tenant credit risk, and acquisition-related dilution constrain upside.

Score
81
Texas Pacific Land Corporation
TPL·Energy
A ★★★★Buy
Current$272.36
Target$292.90
Return+7.5%
Nov 7, 2026

Texas Pacific Land combines scarce Permian mineral rights, exceptional cash generation, and infrastructure monetization opportunities, but commodity exposure and demanding growth expectations limit the margin of safety.

Score
81
Marathon Petroleum Corporation
MPC·Energy
A ★★★★Buy
Current$377.32
Target$405.00
Return+7.3%
Nov 6, 2026

Marathon Petroleum combines large-scale refining, valuable MPLX cash flows and aggressive shareholder returns at a moderately attractive valuation, although exceptional refining margins could normalize and sharply reduce earnings.

Score
81
Assurant, Inc.
AIZ·Financials
A ★★★★Buy
Current$306.87
Target$336.00
Return+9.5%
Nov 6, 2026

Assurant combines recurring specialty insurance and protection-service earnings with strong cash generation and disciplined buybacks, although catastrophe exposure, partner concentration, and a higher share price constrain its margin of safety.

Score
81
Neurocrine Biosciences, Inc.
NBIX·Healthcare
A ★★★★Buy
Current$166.03
Target$203.49
Return+22.6%
Nov 5, 2026

Neurocrine combines strong commercial cash generation with growing rare-disease franchises and promising psychiatric pipeline assets, although INGREZZA concentration, acquisition economics, and clinical failures remain key risks.

Score
81
Viper Energy, Inc.
VNOM·Energy
A ★★★★Buy
Current$41.06
Target$51.66
Return+25.8%
Nov 5, 2026

Viper Energy offers high-margin Permian royalties, visible production growth and attractive normalized cash-flow valuation, although oil-price volatility, acquisition dilution and controlling-shareholder governance remain material risks.

Score
81
Q2 Holdings, Inc.
QTWO·Technology
A ★★★★Buy
Current$67.08
Target$79.50
Return+18.5%
Nov 2, 2026

Q2 combines sticky digital banking subscriptions, double-digit recurring growth, and expanding cash flow, offering attractive long-term compounding potential, although competition, SBC dilution, and implementation delays remain key risks.

Score
81
Parsons Corporation
PSN·Technology
A ★★★★Buy
Current$50.69
Target$61.20
Return+20.7%
Nov 2, 2026

Parsons offers discounted exposure to long-term defense technology and infrastructure demand, supported by record backlog and resilient cash flow, although federal contract volatility and weak capital returns could delay earnings recovery.

Score
81
Stryker Corporation
SYK·Healthcare
A ★★★★Buy
Current$291.86
Target$338.10
Return+15.8%
Nov 1, 2026

Stryker combines a durable medical-device franchise, strong cash generation and a historically compressed valuation, but weaker guidance, cybersecurity exposure and acquisition impairments challenge near-term earnings confidence.

Score
81
Itron, Inc.
ITRI·Technology
A ★★★★Buy
Current$95.82
Target$116.00
Return+21.1%
Nov 1, 2026

Itron offers durable smart-grid infrastructure exposure, growing recurring software revenue and attractive cash-flow valuation, although acquisition execution and uneven utility deployment cycles could constrain earnings growth.

Score
81